Professor Bernardo Leon Rapoport

The Medical Oncology Centre of Rosebank, Johannesburg, South Africa
Department of Immunology, Faculty of Health Sciences, Pretoria, South Africa

Bernardo Rapoport is a Medical Oncologist in private practice in Johannesburg, South Africa.  He has been in private practice as Director of The Medical Oncology Centre of Rosebank since 1993. 

Professor Rapoport is an Extraordinary Professor of Immunology, Faculty of Health Science, University of Pretoria, South Africa. 

After earning his medical degree in 1978 from the University of Buenos Aires in Argentina, he completed an internship at Tel Aviv University in Israel.  Dr Rapoport then specialized in Internal Medicine at the University of the Witwatersrand in Johannesburg, South Africa. He then served as a fellow in Medical Oncology at the University of Pretoria in South Africa, where he became certified as a Medical Oncologist and subsequently worked as a Senior Consultant and Senior Lecturer until 1993.

Professor Rapoport is the current Chairman of the South African Society of Medical Oncology (SASMO), and serves on the Board of Directors of the Multinational Association of Supportive Care in Cancer (MASCC).  He is also the Chairman of the d Neutropenia, Infection and Myelosuppression Study Group and the MASCC Immuno-Oncology Study .

Professor Rapoport is an examiner for the Medical Oncology Certification for the Collage of Medicine of South Africa. He is a former examiner for the M. Med. Clinical Oncology postgraduate exams for the University of Natal.  

Professor Rapoport’s research efforts have focused on cancer supportive care, mainly febrile neutropenia and chemotherapy induced nausea and vomiting (CINV), breast cancer, lung cancer, melanoma ad more recently immuno-oncology translational research, and immune biomarker research.  

His clinical practice focus on solid tumours and haematological malignancies.  His special interests include breast cancer, melanoma, lung cancer, immuno-oncology. 

In recent years Professor Rapoport has been involved in numerous pivotal trials of several groundbreaking therapies to treat various solid tumors, febrile neutropenia and CINV. As frequently invited speaker, Professor Rapoport has delivered more than a 100 lectures at local, regional and international conferences and symposia including ASCO, ESMO, MASCC and SASMO. 

He is also a reviewer for several high impact scientific journals such as Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology and Journal of Supportive Care in Cancer (JSCC). Professor Rapoport is currently a member of the editorial boards of various scientific journals such as ESMO Open and JSCC, where he also currently serves as Associate Editor. He was lead guess editor for Frontiers in Pharmacology, and Frontiers in Immunology.   

He has authored and co-authored various book chapters and has published more than 125 papers in peer reviewed journals including Lancet Oncology, Journal of Clinical Oncology, Annals of Oncology, Journal of Global Oncology, Cancer and Journal of Supportive Care in Cancer.

Professor Rapoport is a member of local, regional and the international Advisory Boards of several multinational pharmaceutical companies including Herron, Tesaro, AstraZeneca, Astellas, Merck-Serono and Merck and Co. 

He is also a frequently invited expert speaker in his field by pharmaceutical companies at a local, regional and international level.  He also lectures for the European School of Oncology (ESO).

Professor Rapoport serves as a member of the MASCC/ESMO Antiemetic Guidelines Working Group, as well as the ESMO Febrile Neutropenia and G-CSF Guidelines Committees. He is also involved on the guidelines of Immuno-Oncology side effects of Immuno-related adverse events.